An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy.

Core Evid · 2012 · PMC3526863 · PMID 23271985

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

65 The results were mixed, as the duration of bacteremia was longer in the linezolid group (median 16 days vs 10 days, P = 0.008) but the 30-day mortality (11% vs 25%, P = 0.08) had a trend toward being lower in the linezolid group that did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.